Mutual of America Capital Management LLC raised its position in Albany Molecular Research Inc. (NASDAQ:AMRI) by 28.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 128,576 shares of the company’s stock after buying an additional 28,345 shares during the period. Mutual of America Capital Management LLC owned 0.37% of Albany Molecular Research worth $2,123,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Emerald Acquisition Ltd. acquired a new stake in shares of Albany Molecular Research during the second quarter worth approximately $3,191,000. Obermeyer Wood Investment Counsel Lllp raised its stake in shares of Albany Molecular Research by 2.3% in the second quarter. Obermeyer Wood Investment Counsel Lllp now owns 1,788,043 shares of the company’s stock worth $24,031,000 after buying an additional 39,893 shares during the last quarter. Evercore Wealth Management LLC raised its stake in shares of Albany Molecular Research by 8.2% in the second quarter. Evercore Wealth Management LLC now owns 1,160,228 shares of the company’s stock worth $15,593,000 after buying an additional 87,787 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Albany Molecular Research by 3.2% in the second quarter. California State Teachers Retirement System now owns 54,496 shares of the company’s stock worth $732,000 after buying an additional 1,672 shares during the last quarter. Finally, Ngam Advisors L.P. raised its stake in shares of Albany Molecular Research by 3.5% in the second quarter. Ngam Advisors L.P. now owns 171,297 shares of the company’s stock worth $2,302,000 after buying an additional 5,831 shares during the last quarter. 71.61% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Albany Molecular Research Inc. (NASDAQ:AMRI) traded up 0.53% during trading on Tuesday, reaching $17.17. The company’s stock had a trading volume of 127,794 shares. Albany Molecular Research Inc. has a 12-month low of $12.45 and a 12-month high of $20.65. The firm’s 50-day moving average price is $16.45 and its 200 day moving average price is $15.11. The company’s market capitalization is $714.10 million.

Albany Molecular Research (NASDAQ:AMRI) last released its quarterly earnings data on Tuesday, November 8th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.04. Albany Molecular Research had a positive return on equity of 7.25% and a negative net margin of 10.48%. The business had revenue of $151.70 million for the quarter, compared to the consensus estimate of $160.75 million. During the same quarter in the previous year, the company posted ($0.12) EPS. The company’s revenue was up 45.0% compared to the same quarter last year. On average, analysts predict that Albany Molecular Research Inc. will post $1.08 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/29/albany-molecular-research-inc-amri-shares-bought-by-mutual-of-america-capital-management-llc.html.

Separately, Morgan Stanley reaffirmed a “buy” rating and issued a $17.00 price target on shares of Albany Molecular Research in a research note on Friday, August 5th.

In other Albany Molecular Research news, SVP Lori M. Henderson sold 6,000 shares of Albany Molecular Research stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $17.00, for a total value of $102,000.00. Following the sale, the senior vice president now owns 51,337 shares of the company’s stock, valued at approximately $872,729. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 17.50% of the stock is owned by company insiders.

About Albany Molecular Research

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

5 Day Chart for NASDAQ:AMRI

Receive News & Stock Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related stocks with our FREE daily email newsletter.